US Stock MarketDetailed Quotes

RLMD Relmada Therapeutics

Watchlist
  • 0.333
  • +0.004+1.31%
Close Feb 14 16:00 ET
  • 0.330
  • -0.003-0.87%
Post 19:40 ET
10.04MMarket Cap-0.12P/E (TTM)

About Relmada Therapeutics Company

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Company Profile

SymbolRLMD
Company NameRelmada Therapeutics
Listing DateOct 10, 2019
Issue Price0.00
Founded2012
CEODr. Sergio Traversa
MarketNASDAQ
Employees20
Fiscal Year Ends12-31
Address2222 Ponce de Leon Boulevard,3rd floor
CityCoral Gables
ProvinceFlorida
CountryUnited States of America
Zip Code33134
Phone1-786-629-1376
Websitehttp://www.relmada.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Sergio Traversa
  • Chief Executive Officer and Director
  • 4.78M
  • Charles S. Ence
  • Chief Accounting and Compliance Officer
  • 2.33M
  • Paul Kelly
  • Director and Chief Operating Officer
  • 1.67M
  • Maged Shenouda
  • Chief Financial Officer and Principal Accounting Officer
  • 2.34M
  • Charles J. Casamento
  • Chairman of the Board
  • 674.90K
  • Fabiana Fedeli
  • Independent Director
  • 1.33M
  • John Glasspool
  • Independent Director
  • 604.77K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More
China's asset revaluation sparks debate: What are mooers buying?